{
    "2021-03-17": [
        [
            {
                "time": "2021-03-17",
                "original_text": "贝达药业MCLA-129获批开展临床试验",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "MCLA-129",
                        "临床试验",
                        "实体瘤"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-03-17",
                "original_text": "贝达药业引进的EGFR/c-Met双特异性抗体获得临床默示许可 | 医麦猛爆料",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "EGFR/c-Met",
                        "双特异性抗体",
                        "临床默示许可"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-03-17",
                "original_text": "贝达药业：MCLA-129注射液获得临床试验批准通知书",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "MCLA-129",
                        "注射液",
                        "临床试验"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-03-17",
                "original_text": "贝达药业(300558.SZ)：MCLA-129注射液用于治疗晚期实体瘤获批临试",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "MCLA-129",
                        "晚期实体瘤",
                        "临床试验"
                    ],
                    "sentiment_score": 0.88,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-03-17",
                "original_text": "贝达药业：药品临床试验申请获批准",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "临床试验",
                        "药品"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-03-17",
                "original_text": "贝达药业治疗晚期实体瘤注射液获批临床试验",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "晚期实体瘤",
                        "注射液",
                        "临床试验"
                    ],
                    "sentiment_score": 0.87,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}